Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8039472 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R... | 10/18/2011 |
| 7452886 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in wh... | 11/18/2008 |
| 7238693 | Aryl carbamate derivatives, preparation and use thereof The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal heal... | 07/03/2007 |
| 7214676 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X1, X2, X3, X4, X, Y, Z, A and Z1 are a... | 05/08/2007 |
| 7109206 | Methods and compositions for the rapid and enduring relief of inadequate myocardial function Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate myocardial f... | 09/19/2006 |
| 7091343 | Compositions useful as inhibitors of protein kinases The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, ... | 08/15/2006 |
| 7071194 | Method for improving respiratory function and inhibiting muscular degeneration The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular ... | 07/04/2006 |
| 6821976 | S-6-hydroxy-buspirone The S-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The S-isomer may provide reduced potential for adverse effects and a longer duration of action compared to the racemic mixture and with busp... | 11/23/2004 |
| 6803368 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalene Compounds of the formula useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced pychoses and dyskinesias, To... | 10/12/2004 |
| 6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which R1, R2, R3 and A are each as defined, and to processes for their preparation an... | 06/01/2004 |
| 6686361 | R-6-hydroxy-buspirone The R-stereoisomer of 6-hydroxy-buspirone is an effective treatment for anxiety, depression, and other psychogenic disorders. The R-isomer exhibits greater receptor specificity than the S-isomer and should have reduced potential for the adverse effects as... | 02/03/2004 |
| 6649614 | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.... | 11/18/2003 |
| 6617329 | Aminoquinazolines and their use as medicaments Compounds of the formula ##STR1## having an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and air-ways, and the preparation thereof... | 09/09/2003 |
| 6579899 | Composition for treatment of stress A method of treating stress in a patient showing stress related symptoms is disclosed, where the method comprises administering to the patient an effective amount of a serotoninergic drug or prodrug. Specific examples of such drugs are described, and incl... | 06/17/2003 |
| 6566361 | Azapirone pain treatment A method of treating pain with acetaminophen comprises the concurrent administration of an azapirone such as buspirone. This combination of agents surprisingly results in a strengthened analgesic response characterized by rapid onset, greater pain relief,... | 05/20/2003 |
| 6541478 | Smoking cessation treatments using naltrexone and related compounds Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrex... | 04/01/2003 |
| 6511982 | Treatment of pain A method of treating pain with acetaminophen comprises the concurrent administration of buspirone. This combination of agents surprisingly results in a morphine-like analgesic response characterized by rapid onset, greater pain relief, and a longer durati... | 01/28/2003 |
| 6268368 | Anionic exchange polymer complexes of buspirone A controlled release form of buspirone medicament is described. This medicament comprises a buspirone in intimate admixture with an anionic exchange polymer complexing agent. These components form a complex upon the addition of water and thereby permit im... | 07/31/2001 |
| 6242447 | Surgical irrigation solution and method for inhibition of pain and inflammation A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at di... | 06/05/2001 |
| 6218395 | Centrally-acting beta-blockers and serotonin-enhancers for the treatment of anxiety disorders and adjustment disorders with anxiety A combination of medicines are administered daily for the relief of the symptoms of an Anxiety Disorder or an Adjustment Disorder With Anxiety. The combination comprises a centrally-acting beta-blocker which passes the brain blood barrier, preferably the ... | 04/17/2001 |
| 6150365 | Anxiety method 6-Hydroxy-8-[4-[4-(2-pyrimidinyl)-piperazinyl]-butyl]-8-azaspiro[4.5]-7,9-d ione and its pharmaceutically acceptable salts and hydrates are useful in the alleviation of anxiety.... | 11/21/2000 |
| 6022869 | Aminoheterocyclic compounds with antithrombotic/anticoagulant effect The invention relates to compounds of formula (I), and pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties; processes for preparing compounds of formula (I) and pharmaceutical compositions.... | 02/08/2000 |
| 6013644 | Spiro-substituted azacycles as modulators of chemokine receptor activity The present invention is directed spiro-substituted azacycles of formula I: (wherein R1, R2, R3, R4, R5, k, l and m are defined herein) which are useful as modulators of chemokine receptor activity. I... | 01/11/2000 |
| 6008222 | Method for oral administration of buspirone and nefazodone An improved method for orally administering buspirone to a human subject wherein the bioavailability of buspirone is increased and its elimination, metabolite formation, and variability of these pharmacokinetic parameters is decreased, the improvement com... | 12/28/1999 |
| 5955459 | Fatty acid-antipsychotic compositions and uses thereof The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and antipsychotic agents. The conjugates are usefull in treating psychotic conditions such as schizophrenia.... | 09/21/1999 |
| 5861399 | Methods and compositions for the rapid and enduring relief of inadequate myocardial function Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate m... | 01/19/1999 |
| 5837280 | Transdermal administration of azapirones In accordance with the present invention, a method and device is provided for administering therapeutically effective doses of the drug azospirone transdermally for treating psychogenic symptomatologies. One embodiment of the present invention comprises a... | 11/17/1998 |
| 5817331 | Transdermal administration of azapirones In accordance with the present invention, a method and device is provided for administering therapeutically effective doses of the drug azospirone transdermally for treating psychogenic symptomatologies. One embodiment of the present invention comprises a... | 10/06/1998 |
| 5633009 | Transdermal administration of azapirones In accordance with the present invention, a method and device is provided for administering therapeutically effective doses of the drug azospirone transdermally for treating psychogenic symptomatologies. One embodiment of the present invention comprises a... | 05/27/1997 |
| 5521183 | Use of 5-HT ligands as anti-pruritic agents The present invention is based on the finding that 5-HT receptor ligands are useful in treating experimental models of clinically encountered pruritus (itch). A 5-HT ligand as used in this specification is a compound capable of binding with some selectivi... | 05/28/1996 |
| 5468749 | Method for treatment of substance addiction Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of substance addiction.... | 11/21/1995 |
| 5461054 | Anthracene-spiro-pyrrolindines The anthracene-spiro-pyrrolidines according to the invention are prepared by reacting either anthracene-spiro-furans or unsubstituted anthracene-spiropyrrolidines with appropriately substituted amines or by reacting unsubstituted anthracene derivatives wi... | 10/24/1995 |
| 5444082 | 3,9-disubstituted-spiro(5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same 3,9-disubstituted-spiro[5.5]undecanes and ##STR1## wherein, R, Y, A, B and n are defined in the specification, pharmaceutical compositions containing same for the treatment of cardiovascular disorders, such as heart failure and hypertension, are disc... | 08/22/1995 |
| 5417987 | Method for controlling bivalves such as zebra mussels A method for enhancing the effect of a toxicant such as chlorine or potassium on bivalve molluscs such as zebra mussels. Application of serotonin or a serotonin agonist in low concentrations inhibits the mussels' ability to close their valves to protect t... | 05/23/1995 |
| 5371087 | 3-<4-substituted-4-piperazinyl)buty]-4-thiazolidinone and related compounds There are disclosed compounds of the formula, ##STR1## where n is 0, 1 or 2; A is ##STR2## where X in each occurrence is independently hydrogen, halogen, loweralkyl, hydroxy, nitro, loweralkoxy, amino, cyano, trifluoromethyl or methylthio; ... | 12/06/1994 |
| 5314888 | Veterinary method for treating inappropriate elimination of urine in household pets The present invention provides a veterinary treatment method for animals suffering from a high arousal state. The treatment employs a class of pharmacologically active compounds having a pyrimidinyl-piperazine ring structure of which the most preferred me... | 05/24/1994 |
| 5258379 | Method of inhibiting gastric acid secretion with n-arylpiperazines The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.... | 11/02/1993 |
| 5229388 | 3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related compounds There are disclosed compounds of the formula, ##STR1## where n is 0, 1 or 2; A is ##STR2## where X in each occurrence is independently hydrogen, halogen, loweralkyl, hydroxy, nitro, loweralkoxy, amino, cyano, trifluoromethyl or methylthio; ... | 07/20/1993 |
| 5194436 | 1-piperazinyl-2-butenes and -2-butynes Novel 1-piperazinyl-2-butenes and -2-butynes, intermediates and processes for the preparation thereof, and methods of treating psychoses utilizing compounds or compositions thereof are disclosed.... | 03/16/1993 |
| 5185329 | Method for treatment of substance addiction Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of substance addiction.... | 02/09/1993 |
